Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board
GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
- GLASGOW, Scotland, Oct. 24, 2023 /PRNewswire/ -- Invizius Limited ("Invizius"), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board.
- Professor Canaud is a leading authority on kidney disease and dialysis.
- Richard Boyd, Chief Executive Officer of Invizius, said: "We are delighted and honored to have Professor Canaud join Invizius at an important time of growth and development for the company.
- Professor Bernard Canaud, commented: "Invizius' unique product H-Guard has the potential to reduce the therapeutic burden and save patients' lives by addressing the inappropriate activation of the complement system.